Also, GLP-1R agonists can protect the heart and kidneys, reduce the risk of cardiovascular events, and delay the progress of diabetic nephropathy, which is especially important for people with diabetes
Each goal requires a clear strategy
The SEMALEAN study (2025): "Semaglutide treatment resulted in a 15% reduction in visceral fat," reports a meaningful reduction in visceral fat during therapy, which is important for reducing metabolic risk
At 10 mg/mL, 2.25 mg equals 22.5 units, which is feasible on a 50-unit or 30-unit syringe where half-unit marks exist
Liraglutide: Sold as Victoza, also controls blood sugar and helps with weight loss but can cause nausea like semaglutide
Take our mood quiz and get personalized recommendations